MAY 1·Stock Titan▲
Executive pay, ownership and governance detailed in Catalyst (NASDAQ: CPRX) 2025 10-K/A
Catalyst Pharmaceuticals Inc. (CPRX) filed an amended 2025 annual report (10-K/A) to provide detailed information on directors, executive officers, corporate governance, executive compensation, and security ownership. The amendment clarifies that no financial statements were added and previously reported results remain unchanged. Key figures from the filing include 2025 net product revenue of $588.8 million, net income of $214.3 million, and a CEO total compensation of $8.18 million with a pay ratio of 26:1.
APR 23·Investing.com South Africa▲
Catalyst Pharmaceuticals stock hits all-time high at $26.63 By Investing.com
Catalyst Pharmaceuticals stock reached an all-time high of $26.63, trading within 1% of its 52-week high, driven by a 12.2% total return over the past year and a 25% gain in the last six months. The company's financial strength is highlighted by holding more cash than debt, and its stock appears undervalued based on InvestingPro analysis with a P/E ratio of 15.65 and a PEG ratio of 0.52. Recent strong Q4 2025 financial results, with EPS and revenue significantly exceeding forecasts, and ongoing research into Duchenne muscular dystrophy further contribute to investor confidence.
